Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

November 1, 2026

Conditions

Breast CancerInsomnia

Interventions

DRUG

Suvorexant Tablets

Suvorexant initially with 10-20 mg for 28 days

OTHER

Placebo Control

Matched Placebo Control for 28 days

Trial Locations (1)

RECRUITING

MUSC Department of Family Medicine, Charleston

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Medical University of South Carolina

OTHER